Rogers Corp (ROG)

Trade ROG now with
6/14/2018 1:02:13 AM Genentech Announces New OCREVUS Data On Long-Term Disability Benefits In Primary Progressive Multiple Sclerosis
6/11/2018 7:02:03 AM Roche Announces Plans To Launch The CoaguChek Vantus System
6/8/2018 3:09:15 PM Genentech Gets FDA Approval For Venclexta Plus Rituxan For People With Previously Treated Chronic Lymphocytic Leukemia
6/7/2018 8:42:08 AM Roche To Showcase New Solutions To Consolidate Automated Molecular Testing, Microbiology Topics At ASM Microbe 2018
6/5/2018 1:23:28 PM Rogers Corp Files Patent Infringement Lawsuit
6/5/2018 1:02:00 AM Genentech: FDA Accepts SBLA And Granted Priority Review For HEMLIBRA
5/29/2018 1:03:12 AM Genentech Says Phase III IMpower130 Study Meets Co-primary Endpoints Of OS And Progression-free Survival
5/21/2018 2:03:48 AM Genentech Announces Full Results From Phase III HAVEN 3 Study Evaluating HEMLIBRA
5/14/2018 1:05:50 AM Genentech To Present New Phase III Data For HEMLIBRA In People With Hemophilia A At WFH 2018
5/14/2018 1:02:36 AM Roche Announces FDA Approval Of An Additional Claim For Cobas Zika Test For Use On Cobas 6800/8800 Systems
5/10/2018 1:04:11 AM Genentech: Phase III IMblaze370 Study Of TECENTRIQ And COTELLIC Did Not Meet Primary Endpoint Of OS Vs Regorafenib
5/8/2018 1:16:07 AM Genentech To Present New Data From Oncology Portfolio At 2018 ASCO Annual Meeting
5/7/2018 1:05:40 AM FDA Grants Priority Review To Genentech’s Cancer Immunotherapy TECENTRIQ (Atezolizumab)
4/26/2018 4:15:26 PM Rogers Corp. Q1 Adj. EPS $1.48 Vs $1.68 Last Year
4/23/2018 1:02:00 AM Genentech Presents New OCREVUS (ocrelizumab) Data At The 70th American Academy Of Neurology Annual Meeting
4/17/2018 1:01:42 AM FDA Grants Breakthrough Therapy Designation For Genentech’s HEMLIBRA In Hemophilia A Without Inhibitors
4/16/2018 1:02:08 AM Genentech To Present New Data At AAN Highlighting Extensive Research For OCREVUS
4/16/2018 1:01:36 AM Roche Gets FDA Clearance For Cobas CT/NG For Cobas 6800/8800 Systems
3/26/2018 1:05:39 AM Genentech: Phase III IMpower150 Study Showed TECENTRIQ, Avastin Plus Carboplatin And Paclitaxel Meet Co-primary Endpoint